Literature DB >> 9878036

What level of hepatitis B antibody is protective?

A D Jack1, A J Hall, N Maine, M Mendy, H C Whittle.   

Abstract

This study assessed the level of vaccine-induced hepatitis B surface antibody that is protective against hepatitis B infection and carriage in The Gambia. Sera from 700 of a cohort of 1041 children vaccinated against hepatitis B in infancy were serially tested for markers of hepatitis B until age 7 years. No absolute level of protection against infection was found, but all children who attained a peak antibody response to vaccination of >=10 IU/L were protected against carriage of hepatitis B surface antigen. Two-thirds of 45 infected children experienced brief infection (determined by loss of core antibody). This transient infection was likely related to surface antibody level. The data support the use of the peak antibody response as the best indicator of protection against carriage and suggest that most infections after vaccination are short-lived.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9878036     DOI: 10.1086/314578

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  97 in total

1.  A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.

Authors:  F Verrier; S Burda; R Belshe; A M Duliege; J L Excler; M Klein; S Zolla-Pazner
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 2.  Correlates of protection induced by vaccination.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

Review 3.  Contributions of humoral and cellular immunity to vaccine-induced protection in humans.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Virology       Date:  2011-01-08       Impact factor: 3.616

4.  HIV and Hepatitis B coinfection among perinatally HIV-infected Thai adolescents.

Authors:  Linda Aurpibul; Pagakrong Lumbiganon; Pope Kolasaraksa; Rawiwan Hansudewechakul; Pattaratida Sa-Nguanmoo; Pawinee Taeprasert; Torsak Bunupuradah; Yong Poovorawan; Virat Sirisanthana; Thanyawee Puthanakit
Journal:  Pediatr Infect Dis J       Date:  2012-09       Impact factor: 2.129

5.  Immunological response to two hepatitis B vaccines administered in two different schedules.

Authors:  K M Girisha; J R Kamat; G Nataraj
Journal:  Indian J Pediatr       Date:  2006-06       Impact factor: 1.967

6.  The effects of aflatoxin exposure on Hepatitis B-vaccine induced immunity in Kenyan children.

Authors:  D Githang'a; R N Wangia; M W Mureithi; S O Wandiga; C Mutegi; B Ogutu; A Agweyu; J-S Wang; O Anzala
Journal:  Curr Probl Pediatr Adolesc Health Care       Date:  2019-05-16

7.  Assessment of hepatitis B virus antibody titers in childhood cancer survivors.

Authors:  Najwa Yahya Fayea; Shaimaa Mohamed Kandil; Khadijah Boujettif; Ashraf Elsayed Fouda
Journal:  Eur J Pediatr       Date:  2017-07-20       Impact factor: 3.183

8.  Immune response to hepatitis B virus vaccine in celiac subjects at diagnosis.

Authors:  Martina Filippelli; Maria Teresa Garozzo; Antonino Capizzi; Massimo Spina; Sara Manti; Lucia Tardino; Carmelo Salpietro; Salvatore Leonardi
Journal:  World J Hepatol       Date:  2016-09-18

9.  Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children.

Authors:  Hilton Whittle; Shabbar Jaffar; Michael Wansbrough; Maimuna Mendy; Uga Dumpis; Andrew Collinson; Andrew Hall
Journal:  BMJ       Date:  2002-09-14

10.  Revaccination of non- and low- responders after a standard three dose hepatitis B vaccine schedule.

Authors:  Ke Han; Xiaoping Shao; Huizhen Zheng; Chenggang Wu; Jianqiong Zhu; Xiaoli Zheng; Yonghui Zhang
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.